To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
March 2023 427 Pages 160 tables/charts Price: $1,995
The $75 billion U.S. weight loss market grew nearly 15% last year from
the depressed level of 2020. Most segments of the market have recovered from the Covid-19 pandemic and recession. The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers is now providing a medical plan.
The frozen diet entrees market and diet soft drinks have shown surprising
strength, but the health clubs industry was devasted by the pandemic and emerges
as a smaller sector. Supply chain disruptions affected the MLM market for meal
replacements into 2021 and 2022, tamping down growth for Herbalife and
Medifast. The ranks of commercial weight loss centers have been thinned out,
and chains had to pivot to virtual client meetings and drop shipping of
Do-it-yourself plans still abound as consumers use free diet &
fitness apps. Many untapped niches still exist. This is a completely revised and updated
analysis of Marketdata’s best-selling biennial study about the U.S. weight loss
market. This is the most comprehensive investigation of the U.S. weight loss
market published by anyone worldwide.
Covered… dollar value & growth rates of all major weight loss market segments (early 1980s to 2022 and 2023 & 2027 forecasts), latest market trends and developments, status
reports for: diet soft drinks, artificial sweeteners, health clubs, commercial diet center chains, multi-level marketing diet plans, retail meal replacements & weight loss supplements, medical programs (weight loss surgery, MDs, hospitals/clinic programs, Rx diet drugs, bariatricians, VLCD programs), low-cal frozen entrees, and the diet books & exercise DVDs market.
New for this edition:
- Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
- How dieter behavior changed with the pandemic
- The skyrocketing market for Rx obesity drugs and MD programs
- 2022 market performance, 2023 & 2027 Forecasts
- The most popular diets today
- Ranking of the leading competitor companies
- Outlook for the 2023 diet season
- Why MLM is a major force in meal replacements sales, tough year in 2022
- The franchising slowdown.
Also included: 34-year revenue analysis of the market through past
recessions and fad diet cycles, comprehensive dieter demographics, weight loss
center franchising, and extensive national/state commercial centers’ operating
ratios. Rankings & revenues of top commercial chains, brand sales, and a Reference Directory. Contains 34 in-depth competitor profiles for: Weight
Watchers, Jenny Craig, NutriSystem, Medifast, Herbalife, Noom, Slim-Fast, Atkins
Nutritionals, HMR, Optifast, Robard, Lindora Clinics, Slimgenics, Ideal Protein,
Profile by Sanford, BeachBody, Metabolic Research, Smart For Life,
Medi-Weightloss, Centers for Medical Weight Loss, Nuviva, JumptStart MD, Dr.
Report also sold by individual chapters at lower price. $99 Overview available.
Sept. 27, 2023 Jenny Craig, a Wellful Inc., brand, has re-launched as a direct-to-consumer platform. The intermittent fasting focused, weight loss brand is now available for home delivery. In addition to home delivery service, consumers also may schedule appointments with weight loss coaches online. In July, Wellful acquired Jenny at an undisclosed amount after the company faced hardships with competition from popular prescription obesity drugs and closed its corporate centers. Along with Jenny Craig, Wellful Inc., is the parent company
Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In December, analysts at SVB Securities projected that Mounjaro sales could reach $26.4 billion by 2030. Novo Nordisk reported that in the first six months of
August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after 46 weeks of treatment in a Phase II dose escalation trial investigating the drug in patients living with obesity without type 2 diabetes (T2D). Boehringer
Aug. 8, 2023 Second quarter 2023 revenue decreased 34.7% to $296.2 million from $453.3 million for the second quarter of 2022, primarily driven by a decrease in the number of active earning OPTAVIA Coaches and the decline in the productivity per active earning OPTAVIA Coach. The average revenue per active earning OPTAVIA Coach was $5,578, compared to $6,667 for the second quarter last year, a decline of 16.3%, driven by continued pressure on customer acquisition, partially offset by the price increase implemented in November 2022. The total number of active earning OPTAVIA